Antitrust: Commission confirms unannounced inspections in pharmaceutical sector


On 30 November 2010, European Commission officials carried out unannounced inspections at the premises of a number of pharmaceutical companies in several Member States. Reason was the Commission's suspicion that they may have acted individually or jointly, notably, to delay generic entry for a particular medicine.

Restrictive business practices and/or the abuse of a dominant market position are prohibited under EU antitrust law (Articles 101 and 102 EU Treaty). The companies in question risk fines and other sanctions if the Commission's allegations are confirmed. EU law provides for a procedure, including rights of defence, allowing the companies at risk to present their position.

LOADING PDF: If there are any problems, click here to download the file.

Published In: Administrative Agency Updates, Antitrust & Trade Regulation Updates, Criminal Law Updates, Health Updates, Intellectual Property Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Peter Kugel, KUGEL LEGAL - European Chemical Law Attorneys | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »